Vanguard Capital Management
PBYI icon

Vanguard Capital Management’s Puma Biotechnology PBYI Stock Holding History

Vanguard Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9M Buy
1,835,643
+17,962
+1% +$132K ﹤0.01% 2601
2026
Q1 		$11.6M Buy
+1,817,681
New +$11.7M ﹤0.01% 2650

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return

Vanguard Capital Management's PBYI Position: Q2 2026 in Review

Vanguard Capital Management increased its Puma Biotechnology (PBYI) stake by 0.99% in Q2 2026, buying an estimated $132K and bringing the position to 1,835,643 shares worth $14.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2601.

Vanguard Capital Management first reported a position in PBYI in Q1 2026 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Vanguard Capital Management held 1,835,643 shares of Puma Biotechnology worth $14.9M as of Q2 2026.
  • Vanguard Capital Management bought 17,962 Puma Biotechnology shares in Q2 2026, an estimated $132K.
  • Puma Biotechnology made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2601 holding.
  • Vanguard Capital Management first reported a position in Puma Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.